1887

Abstract

Cynomolgus macaque monkeys () were immunized twice intramuscularly, either with a conventional non-adjuvanted subunit vaccine or with a candidate immune-stimulating complex (iscom) vaccine, each containing 10 µg envelope glycoprotein of a recent human influenza A(H3N2) virus (A/Netherlands/18/94). In contrast to the macaques vaccinated with the classical subunit vaccine, those immunized with the iscom vaccine developed high titres of specific IgM, IgA and IgG serum antibodies, as well as high titres of haemag- glutination-inhibiting and virus-neutralizing serum antibodies. Also, specific proliferative T cell responses were only found in the iscom-vaccinated monkeys and their levels were similar to those found in monkeys experimentally infected with the homologous virus. Upon intratracheal challenge with the homologous virus, the iscom-vaccinated monkeys were completely protected from detectable virus replication in lungs, pharynx and nose, whereas those vaccinated with the classical subunit vaccines were not, or were only partially protected. The kinetics of specific serum antibody development in the iscom-vaccinated monkeys after challenge were quite similar to those of monkeys after secondary infection with the same virus. In contrast, the post-challenge kinetics of serum antibody development in the monkeys vaccinated with the classical subunit vaccines resembled those of naive monkeys, confirming that these vaccines only provided limited protection in such animals.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-4-757
1997-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/4/9129647.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-4-757&mimeType=html&fmt=ahah

References

  1. Ben-Ahmeida E. T. S., Jennings R., Erturk M., Potter C. W. 1992; The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as iscoms, with FCA, ALH or as infectious virus. Archives of Virology 125:71–86
    [Google Scholar]
  2. Ben-Ahmeida E. T. S., Potter C. W., Gregoriadis G., Adithen C., Jennings R. 1994; IgG subclass response and protection against challenge following immunization of mice with various influenza A vaccines. Journal of Medical Microbiology 40:261–269
    [Google Scholar]
  3. Bradford M. M. 1976; A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248–254
    [Google Scholar]
  4. De Haan A., Wilschut J. 1995; Liposomes and antiviral mucosal immunity. In Liposomes in Biomedical Applications, pp 69–83 Shek P. N. Edited by Chur, Switzerland: Harwood Academic Publishers;
    [Google Scholar]
  5. Ghazi H. O., Potter C. W., Smith T. L., Jennings R. 1995; Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. Journal of Medical Microbiology 42:53–61
    [Google Scholar]
  6. Glück R. 1995; Liposomal presentation of antigens for human vaccines. In Vaccine Design: the Subunit and Adjuvant Approach, pp 325–345 Powell M. F., Newman M. J. Edited by New York: Plenum Press;
    [Google Scholar]
  7. Govaert T. M., Sprenger M. J. W., Dinant G. J., Aretz K., Masurel N., Knottnerus J. A. 1994; Immune response to influenza vaccination of elderly people. A randomized double blind placebo-controlled trial. Vaccine 12:1185–1189
    [Google Scholar]
  8. Gupta R. K., Relyveld E. H., Lindblad E. B., Bizzini B., Ben-Efraim S., Gupta C. K. 1993; Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11:293–306
    [Google Scholar]
  9. Heeg K., Kuon W., Wagner H. 1991; Vaccination of class I major histocompatibility complex (MHC) restricted murine CD8+ T lymphocytes towards soluble antigens : immune stimulating ovalbumin complexes enter the class I MHC antigen pathway and allow sensitization against the immunodominant peptide. European Journal ofImmunology 21:1523–1527
    [Google Scholar]
  10. Hulskotte E. G. J., Geretti A. M., Siebelink K. H. J., Van Amerongen G., Cranage M. P., Rud E. W., Norley S. G., De Vries P., Osterhaus A. D. M. E. 1995; Vaccine induced virus neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). Journal of Virology 69:6289–6296
    [Google Scholar]
  11. Jones P. D., ThaHla R., Morein B., Lövgren K., Ada G. L. 1988; Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms). Scandinavian Journal of Immunology 27:645–652
    [Google Scholar]
  12. Keren G., Segev S., Morag A., Rubinstein E. 1988; Failure of influenza vaccination in the aged. Journal of Medical Virology 25:85–89
    [Google Scholar]
  13. Lövgren K. 1988; The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scandinavian Journal of Immunology 27:241–245
    [Google Scholar]
  14. Lövgren K., Kaberg H., Morein B. 1990; An experimental subunit vaccine (iscom) induced protective immunity to influenza virus infection in mice after a single intranasal administration. Clinical and Experimental Immunology 82:435–439
    [Google Scholar]
  15. Masurel N., Ophof P., De Jong P. 1981; Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. Journal of Hygiene 87:201–209
    [Google Scholar]
  16. Mowat A. M., Donachie A. M., Reid G., Jarrett O. 1991; Immune stimulating complexes containing Quil A and protein antigen prime class I MHC restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 72:317–322
    [Google Scholar]
  17. Mumford J. A., Jesset D., Dunleavy U., Wood J., Hannant D., Sundquist B., Cook R. F. 1994; Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 12:857–863
    [Google Scholar]
  18. Ott G., Barchfeld G. L., Chernoff D., Radhakrishnan R., Van Hoogevest P., Van Nest G. 1995; MF59, design and evaluation of a safe and potent adjuvant for human vaccines. In Vaccine Design: the Subunit and Adjuvant Approach, pp 277–296 Powell M. F., Newman M. J. Edited by New York: Plenum Press;
    [Google Scholar]
  19. Renagar K. B., Small P. A. Jr 1991a; Passive transfer of local immunity to influenza virus infection by IgA antibody. Journal of Immunology 146:1972–1978
    [Google Scholar]
  20. Renagar K. B., Small P. A. Jr 1991b; ImmunoglobulinAmediation of murine nasal anti-influenza virus immunity. Journal of Virology 65:2146–2148
    [Google Scholar]
  21. Rimmelzwaan G. F., Osterhaus A. D. M. E. 1995a; . Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza? Vaccine 13:703–705
    [Google Scholar]
  22. Rimmelzwaan G. F., Osterhaus A. D. M. E. 1995b; A novel generation of viral vaccines based on the iscom matrix. In Vaccine Design: the Subunit and Adjuvant Approach, pp 543–588 Powell M. F., Newman M. J. Edited by New York: Plenum Press;
    [Google Scholar]
  23. Rimmelzwaan G. F., Siebelink K. H. J., Huisman R. C., Moss B., Francis M. J., Osterhaus A. D. M. E. 1994; Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. Journal of General Virology 75:2097–2102
    [Google Scholar]
  24. Strassburg M. A., Greenland S., Sorvillo F. J., Lieb L. E., Habel L. A. 1986; Influenza in the elderly, report of an outbreak and review of vaccine effectiveness reports. Vaccine 4:38–44
    [Google Scholar]
  25. Sundquist B., Lövgren K., Morein B. 1988; Influenza virus iscoms: antibody response in animals. Vaccine 6:49–52
    [Google Scholar]
  26. Takahashi H., Takeshita T., Morein B., Putney S., Germain R. N., Berzofsky J. A. 1990; Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in iscoms. Nature 344:873–875
    [Google Scholar]
  27. Thapar M. A., Parr E. J., Bozzola J. J., Parr M. B. 1991; Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (iscom). Vaccine 9:129–133
    [Google Scholar]
  28. Van Binnendijk R. S., Van Baalen C. A., Poelen M. C. M., De Vries P., Boes J., Cerundolo V., Osterhaus A. D. M. E., Uytdehaag F. G. C. M. 1992; Measles virus transmembrane fusion protein synthesized de novo or presented in iscom is endogenously processed for HLA class I and class II restricted cytotoxic T cell recognition. Journal of Experimental Medicine 176:119–128
    [Google Scholar]
  29. Van Binnendijk R. S., Van Der Heijden R. W. J., Van Amerongen G., Uytdehaag F. G. C. M., Osterhaus A. D. M. E. 1994; Viral replication and development of specific immunity in macaques after infection with different measles virus strains. Journal of Infectious Diseases 170:443–448
    [Google Scholar]
  30. Yewdell J. W., Frank E., Gerhard W. 1981; Expression of influenza A virus internal antigens on the surface of infected P815 cells. Journal of Immunology 126:1814–1819
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-4-757
Loading
/content/journal/jgv/10.1099/0022-1317-78-4-757
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error